Uterine mullerian adenosarcoma in very young patient

Introduction: Uterine adenosarcoma mostly seen in elderly and there are limited data on appropriate approach in premenopausal patient and the accurate prognosis. Herein we aimed to present a young case of Müllerian adenosarcoma of uterus which had only 9 years old. Case report: A 9year old pre pubertal girl presented to the gynecology department of Isfahan University of Medical Sciences-Iran with the vaginal bleeding. An intrauterine mass was noted via hysteroscopic examination as the reason of abnormal bleeding. The final pathology revealed Müllerian adenosarcoma of uterus. Subsequently hysterectomy was done due to persistent perfused vaginal bleeding; with ovarian preservation. Conclusion: Due to rarity of Müllerian adenosarcoma, the gynecologists and pathologists should be reminded about the possibility of the diagnosis in young patients too.

Müllerian adenosarcoma; Uterine; Mesenchymal tumor; Childhood; Vaginal bleeding; Adolescent.

[1] Wu R.I., Schorge J.O., Cin P.D., Young R.H., Oliva E.: “Müllerian adenosarcoma of the uterus with low-grade sarcomatous overgrowth characterized by prominent hydropic change resulting in mimicry of a smooth muscle tumor”. Int. J. Gynecol. Pathol., 2014, 33, 573.

[2] Nasioudis D., Chapman-Davis E., Frey M., Holcomb K.: “Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma”. J. gynecol. oncol. 2017, 19, 28.

[3] Patrelli T.S., Gizzo S., Di Gangi S., Guidi G., Rondinelli M., Nardelli G. B.: “Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature”. BMC Cancer, 2011, 11, 236.

[4] Goh C., Lin X.H., Chin P.S., Lim Y.K.: “Uterine preservation in a young patient with adenosarcoma of the uterus–Case report and review of literature”. Gynecol. Oncol.Rep., 2018, 25, 27.

[5] Lee Y., Kim D., Suh D., Kim J., Kim Y., Kim Y., et al.: “Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience”. World J. Surg. oncol., 2017, 15, 87.

[6] Yoon A., Park J.Y., Park J.Y., Lee Y.Y., Kim T.J., Choi C.H., et al.: “Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases”. Gynecol. Oncol., 2014, 132, 70.

[7] Li N., Wu L.Y., Zhang H.T., An J.S., Li X.G., Ma S.K.: “Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases”. Gynecol. Oncol., 2008, 108, 306.

[8] Sangle N.A., Lele S.M.: “Uterine mesenchymal tumors”. Indian J. Pathol. Microbiol., 2011, 54, 243.

[9] Ramos P., Ruiz A., Carabias E., Piñero I., Garzon A., Alvarez I.: “Mül-lerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature”. Gynecol. oncol., 2002, 84, 161.

[10] Morales F.D.A., Medina R.M.L., Trujillo L.M., Beltrán M.I., Dulcey I.C.: “Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: A case report of aggressive disease in a young patient”. Int.J. Sur. Case Rep., 2016, 27, 155.